Arkolith/Insider Trading/XFOR/Form 4

Kirske David

Chief Financial OfficerX4 Pharmaceuticals, Inc (XFOR) · full profile →Form 4 · filed Aug 14, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 14, 2025Grant(A)193K—$0193K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 14, 2025Grant(A)353K—$0353K
Aug 12, 2025Grant(A)1.1M—$01.1M

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-25-040440) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML